Table 2.
Comparison of oncologic outcome between planned excision and unplanned excision
| Outcome | PE (CIs) | UE (CIs) | P a |
|---|---|---|---|
| 5‐year DSS (%) | |||
| Extremity and trunk | 78.6 (73.1–84.1) | 79.7 (72.6–86.8) | 0.801 |
| Stage I | 100 | 97.1 (91.6–100) | 0.315 |
| Stage II | 84.9 (77.3–92.5) | 79.9 (69.9–89.9) | 0.470 |
| Stage III | 68.7 (59.7–77.7) | 61.2 (44–78.4) | 0.326 |
| Head and neck | 100 | 75 (32.5–100) | 0.386 |
| Retroperitoneal | 59.3 (23–95.6) | 33.3 (0–86.6) | 0.187 |
| 5‐year MFS (%) | |||
| Extremity and trunk | 65.9 (59.6–72.2) | 72.7 (64.9–80.5) | 0.088 |
| Stage I | 95 (85.4–100) | 80.3 (65.6–95) | 0.183 |
| Stage II | 73.7 (64.7–82.7) | 74.9 (64.3–85.5) | 0.909 |
| Stage III | 53.2 (43.8–62.6) | 58 (39.6–76.4) | 0.573 |
| Head and neck | 100 | 100 | − |
| Retroperitoneal | 66.7 (35.9–97.5) | 100 | 0.351 |
| 5‐year LRFS (%) | |||
| Extremity and trunk | 88.9 (84.4–93.4) | 86.9 (80.8–93) | 0.984 |
| Stage I | 100 | 82.7 (68.8–96.6) | 0.072 |
| Stage II | 89 (82.5–95.5) | 92.9 (87–98.8) | 0.369 |
| Stage III | 86.4 (79–93.8) | 75.5 (57.3–93.7) | 0.407 |
| Head and neck | 80 (44.9–100) | 80 (44.9–100) | 0.937 |
| Retroperitoneal | 71.1 (35.8–100) | 33 (0–86.6) | 0.018 |
| Intermediate tumor | 97.5 (91.6–100) | 100 | 0.509 |
PE, Planned excision; UE, Unplanned excision; CIs, 95% confidence intervals; DSS, Disease‐specific survival; MFS, Metastasis‐free survival; LRFS, Local‐recurrence‐free survival; −, No event occurred in both groups.
a
Log‐rank test.